Felix-Tellez Francisco A, Morel-Cerda Eliana C, Jiménez-Castillo Raúl A, Valdovinos-García Luis R, Gómez-Escudero Octavio, Valdovinos-Díaz Miguel Á, Coss-Adame Enrique, Velasco José A Velarde-Ruiz, Monjaraz Erick M Toro, Montijo-Barrios Ericka, Solís-Ortega Alberto A, Frazier Rosita De Jesus, Venkatesan Thangam, Remes-Troche José M
Digestive Physiology and Motility Lab, Instituto de Investigaciones Medico-Biologicas, Veracruz, México.
Hospital Civil de Guadalajara Unidad Hospitalaria Fray Antonio Alcalde, Guadalajara, Jalisco, México.
J Neurogastroenterol Motil. 2025 Jul 30;31(3):330-339. doi: 10.5056/jnm24182.
BACKGROUND/AIMS: Cyclic vomiting syndrome (CVS) and cannabinoid hyperemesis syndrome (CHS) are emerging gastroduodenal disorders with a growing prevalence. However, little is known about their prevalence and clinical characteristics in Latin American populations, particularly in Mexico. This study aims to explore the clinical presentation of CVS and CHS in Mexico.
A cross-sectional study was conducted in 5 medical centers across Mexico, involving patients diagnosed with CVS or CHS based on the Rome IV criteria. Data collected included sociodemographic variables, substance use, comorbidities, and clinical characteristics, with a specific focus on the relationship between substance use, particularly cannabis, and symptomatology.
The study included 46 patients, with 30 diagnosed with CVS and 16 with CHS. CVS patients were younger (median age 23 years) compared to CHS patients (median age 27 years; = 0.043). CHS patients exhibited higher tobacco consumption (50.0% vs 26.7%; = 0.019) and risky alcohol use (31.3% vs 0.0%; = 0.003). Cannabis use was reported by 13.3% of CVS patients. The time to diagnosis was longer for CVS (35.4 ± 9.8 months) compared to CHS (26.5 ± 16.0 months; = 0.016). No significant differences were found in the number of hospital admissions, as well as length of stay between patients with CVS and CHS.
This study presents the first detailed analysis of CVS and CHS in the Mexican population, revealing some demographic and clinical differences from global data. These findings highlight the importance of developing region-specific guidelines for diagnosing and managing these conditions, especially given Mexico's changing cannabis policies.
背景/目的：周期性呕吐综合征（CVS）和大麻素类呕吐综合征（CHS）是新出现的胃十二指肠疾病，患病率不断上升。然而，对于拉丁美洲人群，尤其是墨西哥人群中它们的患病率和临床特征知之甚少。本研究旨在探讨墨西哥CVS和CHS的临床表现。
在墨西哥的5个医疗中心进行了一项横断面研究，纳入根据罗马IV标准诊断为CVS或CHS的患者。收集的数据包括社会人口统计学变量、物质使用情况、合并症和临床特征，特别关注物质使用，尤其是大麻与症状之间的关系。
该研究纳入了46例患者，其中30例诊断为CVS，16例诊断为CHS。CVS患者比CHS患者更年轻（中位年龄23岁 vs 中位年龄27岁；P = 0.043）。CHS患者的烟草消费量更高（50.0% vs 26.7%；P = 0.019），且存在危险饮酒情况（31.3% vs 0.0%；P = 0.003）。13.3%的CVS患者报告使用过大麻。CVS的诊断时间比CHS更长（35.4±9.8个月 vs 26.5±16.0个月；P = 0.016）。CVS和CHS患者的住院次数以及住院时间没有显著差异。
本研究首次对墨西哥人群中的CVS和CHS进行了详细分析，揭示了与全球数据在一些人口统计学和临床方面的差异。这些发现凸显了制定针对这些疾病的诊断和管理的地区特异性指南的重要性，特别是考虑到墨西哥不断变化的大麻政策。
